JP Morgan maintains Dentsply Sirona at Neutral, lowers price target to $10 from $12

JP Morgan retained its Neutral rating for Dentsply Sirona but reduced its price target to $10 from $12, a 16.7% decrease. This implies a 5.7% upside from the Nov 6 close of $9.46. Recent analyst targets for the company range from $10 to $13.

Original reporting
Published Nov 7, 2026, 2:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 2:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Dentsply Sirona at Neutral, lowers price target to $10 from $12 — source image
Decision brief

The 30-second read

Low
01

Why it matters

A 16.7% target reduction may trigger modest sell pressure, though the stock still trades near the new target.

02

Market read

The downgrade provides a small, immediate trading signal for DENT.

03

What to watch

Recent product launches and contract wins not mentioned could support upside.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst price target adjustments are routine but can influence short-term price action.

Market effects

Minimal impact on the broader dental equipment sector.

Limited to U.S. investors tracking the stock.

Low global relevance.

Counterpoint

The target cut may be overly cautious; the stock could be undervalued.

Key entities

  • JP Morgan

    Equity research analyst lowering Dentsply Sirona price target.

  • Dentsply Sirona

    Dental equipment manufacturer (ticker DENT).

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.